Kezar Life Sciences, Inc. (KZR) Income from Continuing Operations (2017 - 2026)

Kezar Life Sciences has reported Income from Continuing Operations for 10 years, with the latest figure at 7728000.0 in Q1 2026.

• Quarterly Income from Continuing Operations rose 53.32% year-over-year to 7728000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 53640000.0 (up 32.39% YoY) and the FY2025 annual result came in at 164839000.0, up 10.72% from the prior year.
• Income from Continuing Operations grew to 7728000.0 in Q1 2026 per KZR's latest filing, from 13942000.0 in the prior quarter.
• Over five years, Income from Continuing Operations peaked at 7728000.0 in Q1 2026 and troughed at 44246000.0 in Q3 2022.
• A 5-year average of 23440941.18 and a median of 20672000.0 in 2024 frame the typical range for Income from Continuing Operations.
• The sharpest annual moves came in 2022 and 2026: Income from Continuing Operations sank 94.06% in 2022, then jumped 53.32% in 2026.
• Over 5 years, Income from Continuing Operations stood at 20434000.0 in 2022, then sank by 70.07% to 34753000.0 in 2023, then soared by 41.82% to 20218000.0 in 2024, then soared by 31.04% to 13942000.0 in 2025, then soared by 44.57% to 7728000.0 in 2026.
• According to Business Quant data, Income from Continuing Operations over the past three periods registered 7728000.0, 13942000.0, and 14126000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.